Literature DB >> 22990849

Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection.

Jonathan S Zipursky1, Tivon I Sidorsky, Carolyn A Freedman, Misha N Sidorsky, Kathryn B Kirkland.   

Abstract

BACKGROUND: Fecal microbiota transplantation (FMT), a safe, effective alternative therapy for recurrent Clostridium difficile infection (CDI), is infrequently used, in part because of an assumption that patients are unwilling to consider FMT because of its unappealing nature.
METHODS: Through a structured survey, including hypothetical case scenarios, we assessed patient perceptions of the aesthetics of FMT and their willingness to consider it as a treatment option, when presented with scenarios involving recurrent CDI.
RESULTS: Four hundred surveys were distributed; 192 (48%) were returned complete. Seventy percent of respondents were female; 59% were >49 years of age. When provided efficacy data only, 162 respondents (85%) chose to receive FMT, and 29 (15%) chose antibiotics alone. When aware of the fecal nature of FMT, 16 respondents changed their choice from FMT to antibiotics alone, but there was no significant change in the total number choosing FMT (154 [81%]; P = .15). More respondents chose FMT if offered as a pill (90%; P = .002) or if their physician recommended it (94%; P < .001). Respondents rated all aspects of FMT at least "somewhat unappealing," selecting "the need to handle stool" and "receiving FMT by nasogastric tube" as most unappealing. Women rated all aspects of FMT more unappealing; older respondents rated all aspects less unappealing. Most respondents preferred to receive FMT in the hospital (48%) or physician's office (39%); 77% were willing to pay out-of-pocket for FMT.
CONCLUSIONS: Patients recognize the inherently unappealing nature of FMT, but they are nonetheless open to considering it as a treatment alternative for recurrent CDI, especially when recommended by a physician.

Entities:  

Mesh:

Year:  2012        PMID: 22990849     DOI: 10.1093/cid/cis809

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  51 in total

1.  Gastroenterologist perceptions of faecal microbiota transplantation.

Authors:  Sudarshan Paramsothy; Alissa J Walsh; Thomas Borody; Douglas Samuel; Johan van den Bogaerde; Rupert Wl Leong; Susan Connor; Watson Ng; Hazel M Mitchell; Nadeem O Kaakoush; Michael A Kamm
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

2.  Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study.

Authors:  Christopher Staley; Matthew J Hamilton; Byron P Vaughn; Carolyn T Graiziger; Krista M Newman; Amanda J Kabage; Michael J Sadowsky; Alexander Khoruts
Journal:  Am J Gastroenterol       Date:  2017-02-14       Impact factor: 10.864

Review 3.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

4.  Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: What's Old Is New Again?

Authors:  Nuntra Suwantarat; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

5.  Gut Health in the era of the human gut microbiota: from metaphor to biovalue.

Authors:  Vincent Baty; Bruno Mougin; Catherine Dekeuwer; Gérard Carret
Journal:  Med Health Care Philos       Date:  2014-11

Review 6.  Scaling Safe Access to Fecal Microbiota Transplantation: Past, Present, and Future.

Authors:  Ryan Eliott; Pratik Panchal; Shrish Budree; Alex Scheeler; Geraldine Medina; Monica Seng; Wing Fei Wong; Thomas Mitchell; Zain Kassam; Jessica R Allegretti; Majdi Osman
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

7.  Physician attitudes toward the use of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection.

Authors:  Jonathan Samuel Zipursky; Tivon I Sidorsky; Carolyn A Freedman; Misha N Sidorsky; Kathryn B Kirkland
Journal:  Can J Gastroenterol Hepatol       Date:  2014-04-09

Review 8.  Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.

Authors:  Marie Céline Zanella Terrier; Martine Louis Simonet; Philippe Bichard; Jean Louis Frossard
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

9.  Fecal Microbiota Transplantation: A Review of Emerging Indications Beyond Relapsing Clostridium difficile Toxin Colitis.

Authors:  Woo Jung Lee; Lakshmi D N Lattimer; Sindu Stephen; Marie L Borum; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-01

Review 10.  Faecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection: current promise and future needs.

Authors:  Mark J Koenigsknecht; Vincent B Young
Journal:  Curr Opin Gastroenterol       Date:  2013-11       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.